2 results
Approved WMOWill not start
• To evaluate the efficacy of JTT-251 in participants with heart failure with reduced ejection fraction (HFrEF)• To evaluate the safety and tolerability of JTT-251 following administration for 24 weeks in participants with HFrEF• To evaluate the…
Approved WMORecruiting
To demonstrate superiority in the metastasis-free survival (MFS) of men with high risk NM-CRPC treated with apalutamide versus placeboSecondary Objective:To compare the overall survival (OS) of men with high risk NM-CRPC treated with apalutamide…